What is the proper administration and usage of Depo Provera (medroxyprogesterone acetate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Depo Provera Administration and Usage

Administer Depo Provera (medroxyprogesterone acetate) as 150 mg intramuscularly every 3 months (13 weeks), with a grace period allowing injections up to 2 weeks late (15 weeks total) without requiring backup contraception. 1, 2, 3

Administration Schedule and Timing

  • Give the first injection only during the first 5 days of a normal menstrual period, or within the first 5 days postpartum if not breastfeeding, or at 6 weeks postpartum if exclusively breastfeeding. 3

  • Repeat injections every 13 weeks, with up to a 2-week grace period (total 15 weeks from last injection) without requiring additional contraceptive protection. 1, 2, 3

  • If the interval exceeds 15 weeks, perform a pregnancy test before administering the next injection. 3

Route and Technique

  • Administer 150 mg by deep intramuscular injection into the gluteal or deltoid muscle. 3

  • Vigorously shake the vial or prefilled syringe immediately before use to ensure uniform suspension. 3

  • The subcutaneous formulation (DMPA-SC 104 mg) is an alternative that can be provider-administered or self-administered (off-label), offering equivalent efficacy to the intramuscular formulation. 1, 2, 4

Self-Administration Option

  • Self-administered subcutaneous DMPA-SC is now recommended by the CDC as an additional approach that improves contraceptive access and reproductive autonomy, though this is technically off-label use. 1, 2

  • Critical implementation elements include: instruction on self-injection technique (in-person or via telemedicine), sharps disposal guidance, access to follow-up care, reinjection reminders, and addressing administrative issues like ordering and billing. 1, 2

  • Self-administered DMPA-SC has demonstrated higher continuation rates compared to provider-administered formulations. 2

Duration of Use

  • Do not limit Depo Provera use to 2 years, as the benefits of preventing unintended pregnancy generally outweigh the risks of bone density loss, according to ACOG. 2, 5

  • For patients using DMPA beyond 2 years, counsel about skeletal health measures: daily calcium intake of 1,300 mg, vitamin D 600 IU, regular weight-bearing exercise, and smoking cessation. 2, 5

  • Routine bone density monitoring is not recommended after 2 years of use unless other osteoporosis risk factors are present. 5

Mechanism and Efficacy

  • Depo Provera inhibits gonadotropin secretion, preventing follicular maturation and ovulation while causing endometrial thinning. 3

  • The contraceptive efficacy is extremely high, with zero pregnancies reported in Phase 3 studies totaling 16,023 woman-cycles of exposure, comparable to modern copper IUDs. 6, 4

  • Peak plasma concentrations occur at approximately 3 weeks, with levels decreasing exponentially and becoming undetectable between 120-200 days post-injection. 3

Return to Fertility

  • Counsel patients that return to fertility may be delayed 9-18 months after discontinuation, with median time to ovulation being 30 weeks. 2, 5, 7

  • Women with lower body weights conceive sooner than those with higher body weights after discontinuing DMPA. 3

  • If amenorrhea persists beyond 18 months after discontinuation, further evaluation is warranted as this exceeds the expected recovery timeframe. 8

Side Effect Management

  • The most common side effect is menstrual irregularity, including spotting, irregular bleeding, and amenorrhea (which occurs in most users over time). 6, 9

  • For spotting or light bleeding, consider NSAIDs for 5-7 days. 2, 8

  • Weight gain is common; weight gain >5% at 6 months is a strong predictor of future excessive weight gain with ongoing use. 5

  • Pre-use counseling about menstrual changes is essential to minimize discontinuation due to bleeding patterns. 5, 6

Advantages Over Other Methods

  • DMPA has no appreciable effects on blood pressure or thrombosis risk, providing an advantage over combined oral contraceptives. 6

  • It is independent of intercourse timing and user memory (except for remembering quarterly appointments), which is advantageous for women with irregular lifestyles. 6

  • For breastfeeding women, DMPA causes no adverse effects on lactation, unlike some other hormonal methods. 10

Common Pitfalls to Avoid

  • Do not discontinue DMPA at 2 years based solely on duration concerns, as this increases risk of unintended pregnancy without clear benefit. 5

  • Do not routinely order bone density scans after 2 years unless other osteoporosis risk factors are present. 5

  • Do not assume amenorrhea after discontinuation is solely due to prior DMPA use without ruling out pregnancy and other causes, especially if amenorrhea persists beyond 18 months. 8

  • Ensure patients understand that DMPA is temporarily irreversible during its 3-month duration, so side effects cannot be immediately withdrawn. 6, 10

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Depo Provera Administration and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Duration of Provera (Medroxyprogesterone Acetate) Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Depo Provera. Position paper on clinical use, effectiveness and side effects.

The British journal of family planning, 1999

Guideline

Workup for Secondary Amenorrhea Following Depo Provera Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Depo-Provera: an injectable contraceptive.

American family physician, 1994

Research

Experience with medroxyprogesterone acetate (Depo-Provera) as an injectable contraceptive.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1977

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.